CA Patent

CA3173808A1 — Methods of treating apol-1 dependent focal segmental glomerulosclerosis

Assigned to Vertex Pharmaceuticals Inc · Expires 2021-09-10 · 5y expired

What this patent protects

This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. Compound I The application also describes pharmaceutical compositions comprising Compound I and/or a …

USPTO Abstract

This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. Compound I The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3173808A1
Jurisdiction
CA
Classification
—
Expires
2021-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.